Kymera CEO Sells $6 Million in Stock After Significant Share Price Increase

Nello Mainolfi, the CEO of Kymera Therapeutics (NASDAQ:KYMR), sold $6 million worth of stock following a 170% increase in share price over the past year. The sale was conducted under a Rule 10b5-1 trading plan and involved exercising options before selling shares at an average price of $119 per share.

By Jonathan Ponciano, The Motley Fool Sun, July 12, 2026 at 11:57 PM GMT+3 4 min read · Yahoo Finance · July 12, 2026, 20:57 UTC

Tickers: $KYMR

Topics: biotech insider_trading Kymera Therapeutics

Read the full article at Yahoo Finance

More World news

Teekay Tankers Shares Decline Despite Q3 Earnings Beat and New Vessel Orders Seeking Alpha · November 12, 2026, 18:27 UTC
U.S. 30-Year Treasury Auction Yields Rise as Demand Weakens Seeking Alpha · November 12, 2026, 18:30 UTC
Nvidia Names Colette Kress Interim CEO Following Jensen Huang's Resignation Motley Fool · November 12, 2026, 18:26 UTC
Bit Digital Reports Q3 2026 Net Income of $28.5 Million Amid Revenue Decline Motley Fool · November 12, 2026, 18:26 UTC
EZCORP Reports Strong Q4 2026 Results with Significant EBITDA and Revenue Growth Motley Fool · November 12, 2026, 18:16 UTC
Sabre Corp Shares Decline Following Travelport Denial of Merger Speculation Seeking Alpha · November 12, 2026, 18:21 UTC
Lufax Reports Third Quarter 2026 Net Loss Amid Rising Credit Impairment Costs Motley Fool · November 12, 2026, 18:15 UTC
Avantor Reports Return to Organic Revenue Growth in Third Quarter 2026 Motley Fool · November 12, 2026, 18:15 UTC
MGP Ingredients Rebrands to Sempreon and Announces Strategic Shift Toward Ready-to-Drink Products Motley Fool · November 12, 2026, 18:15 UTC
ICON Reports Q3 2026 Revenue of $2 Billion and Accelerating Book-to-Bill Ratio Motley Fool · November 12, 2026, 18:15 UTC